 |
 |
| 5-Year Data |
|
|
See the results of the longest reported controlled clinical study of male pattern hair loss. |
|
|
| View study results. |
|
 |
 |
|
|
|
|
| Overview of PROPECIA® (finasteride) |
|
 |
|
|
Prescribing PROPECIA
|
|
 |
Start early: hair loss is a progressive condition—those patients left untreated may continue to lose hair. |
| |
|
Recommend 12 months of therapy to evaluate the potential benefit of PROPECIA. (It may take up to 12 months to fully evaluate the effectiveness of PROPECIA.) |
| |
|
Stopping treatment leads to a gradual reversal of the beneficial effects within 12 months. Further treatment is unlikely to be of benefit if the drug has not worked within 12 months. |
|
|
|
|
Prescribe PROPECIA in PROPAK®* (a 3-month convenience pack) for appropriate patients. |
|
 |
|
About PROPECIA
|
|
|
PROPECIA is the first oral therapy indicated for the treatment of male pattern hair loss in MEN ONLY. Safety and efficacy were demonstrated in men, aged 18 to 41, with mild to moderate hair loss of the vertex and anterior mid-scalp area. Efficacy in bitemporal recession has not been established. |
|
PROPECIA is not indicated in women or children. |
|
PROPECIA is contraindicated in women when they are or may potentially be pregnant. Finasteride may cause abnormalities of the external genitalia of a male fetus of a pregnant woman. |
| |
|
In clinical studies of 1 year for PROPECIA, each drug-related sexual adverse event occurred in less than 2% of men. Discontinuation due to drug-related sexual adverse experiences was 1.2% in the group treated with PROPECIA and 0.9% in the placebo-treated group. Reported drug-related sexual adverse experiences included decreased libido (1.8% vs 1.3%, placebo), erectile dysfunction (1.3% vs 0.7%, placebo), and ejaculation disorders (1.2% vs 0.7%, placebo), primarily decreased volume of ejaculate (0.8% vs 0.4%, placebo). Resolution occurred in the 1-year studies in men who discontinued therapy with PROPECIA due to these sexual side effects. The incidence of each of the above side effects decreased to <0.3% by the fifth year of treatment with PROPECIA. |
|
Convenient, once-a-day dosing in tablet form. |
|
PROPECIA has been used by more than 1 million men in the United States since the launch of PROPECIA in 1998.† |
| |
|
Before prescribing PROPECIA, please read the Prescribing Information. |
|
|
| * |
PROPAK is a registered trademark of Merck & Co., Inc. |
| † |
NDCHealth, cumulative total patients. |
|
|
